As lung radiofrequency ablation increases in use, researchers are identifying factors that produce two of the most common complications: tumor recurrence and pneumothorax.
As lung radiofrequency ablation increases in use, researchers are identifying factors that produce two of the most common complications: tumor recurrence and pneumothorax.
Dr. Alice Gillams and Dr. William Lees from University Hospital London found that tumor size and location have the biggest impact on recurrence, while the number of tumors and the anticipated electrode trajectory influence the rate of pneumothorax. They reported their findings at the 2007 European Congress of Radiology.
In their retrospective review (which won first prize in the interventional section), researchers found that recurrence was more common in larger tumors (mean 2.6 cm) and those centrally located and in tumors smaller than 3.5 cm treated with expandable electrodes. A peripheral location-within 5 mm of the pleura, for example-was significantly associated with lower rates of recurrence.
Factors associated with pneumothorax following lung biopsy are well described, but they don't necessarily apply to RFA because larger electrodes, multiple electrode positions, long dwell times, and, often, the need to target multiple tumors are necessary, Gillams said. In a second retrospective review, the U.K. reasearcher found that the length of electrode trajectory through aerated lung, number of tumors ablated, and number of electrode positions were the most significant factors influencing pneumothoraces. While the number of patients with emphysema was small, 67% of these patients developed pneumothorax.
"Pneumothorax is a common side effect of doing this procedure, but it doesn't have to be a scary complication," Gillams said. "Most interventional radiologists have an aspiration needle or drainage catheter at the ready. But if you're treating a patient with many tumors, or one with a lot of aerated lung to cross, you can anticipate a high risk of pneumothorax."
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.